Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
Institute of Hematology & Blood Diseases Hospital, China
Sanofi
M.D. Anderson Cancer Center
Medical College of Wisconsin
Gilead Sciences
University of Florida
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc.
OHSU Knight Cancer Institute
Eastern Cooperative Oncology Group
OHSU Knight Cancer Institute
M.D. Anderson Cancer Center
Emory University
University of California, San Diego
Therapeutic Advances in Childhood Leukemia Consortium
Technische Universität Dresden
St. Jude Children's Research Hospital
University of California, San Francisco
Therapeutic Advances in Childhood Leukemia Consortium
Children's Mercy Hospital Kansas City
St. Petersburg State Pavlov Medical University
St. Jude Children's Research Hospital
Centre Leon Berard
Weill Medical College of Cornell University
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
University of Ulm
Masonic Cancer Center, University of Minnesota
St. Jude Children's Research Hospital
OHSU Knight Cancer Institute
University of Washington
Fred Hutchinson Cancer Center
St. Jude Children's Research Hospital
University of Pittsburgh
Roswell Park Cancer Institute
OHSU Knight Cancer Institute
Hoffmann-La Roche
Karolinska University Hospital
Washington University School of Medicine
Washington University School of Medicine
Hoffmann-La Roche
PETHEMA Foundation
Texas Oncology Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
European Organisation for Research and Treatment of Cancer - EORTC
M.D. Anderson Cancer Center